Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +38.61%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +36.94%
#4 OriginTrail OriginTrail +22.27%
#5 ApeX ApeX +19.21%
#6 UnifAI Network UnifAI Network +17.65%
#7 Morpho Morpho +17.47%
#8 龙虾 (Lobster) 龙虾 (Lobster) +16.01%
#9 Non-Playable Coin Non-Playable Coin +15.71%
#10 Pendle Pendle +14.97%
Coin of the day
Smilek to the Bank Smilek to the Bank
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rang in aandelen #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$50.82
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$102.09M
Verandering (1 dag)
1.90%
Verandering (1 jaar)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Categorie

Healthcare
P/B-ratio voor Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Hemab Therapeutics Holdings, Inc. Common Stock is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Hemab Therapeutics Holdings, Inc. Common Stock van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH